Scientists warn Trump immigration ‘pause’ will harm biopharma innovation

President Donald Trump’s decision to bar most employment-based visas through year-end could have a broad impact on the U.S. biopharma industry, which is heavily dependent on temporary and permanent immigrants to fill jobs from junior scientists to CEOs.

In addition to the proclamation, a

Read the full 439 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers